Pretreatment with divided doses of steroids strongly decreases side effects of OKT3

This publication has 35 references indexed in Scilit:

• Complement activation during OKT3 treatment: A possible explanation for respiratory side effects
  Kidney International, 1993
• High-Dose Methylprednisolone Inhibits the OKT3-lnduced Cytokine-Related Syndrome
  Nephron, 1993
• EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3-INDUCED ACUTE SYNDROME
  Transplantation, 1992
• OKT3 first-dose reaction: Association with T cell subsets and cytokine release
  Kidney International, 1991
• IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
  Transplantation, 1990
• Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation
  European Journal of Immunology, 1990
• Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-α
  New England Journal of Medicine, 1989
• A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants
  New England Journal of Medicine, 1985
• EVOLVING USE OF OKT3 MONOCLONAL ANTIBODY FOR TREATMENT OF RENAL ALLOGRAFT REJECTION
  Transplantation, 1984
• Administration of prednisolone in vivo affects the ratio of and the LDH-isoenzyme pattern of human T lymphocytes
  Clinical Immunology and Immunopathology, 1984